Paper Details

  1. Home
  2. Paper Details

A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome.

Author: ColyvasKim, DwyerPeter, FitzgeraldElizabeth, ManningJane, MurrayChristine, RosamiliaAnna

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

While abobotulinumtoxin A (AboBTXA) did not show overall improvement in total OLS score for patients with chronic refractory interstitial cystitis/bladder pain syndrome (IC/BPS), it did show significant benefit in a small number of patients. The absence of posttreatment UTI was associated with a better response to AboBTXA.
Paper Details　
Original Abstract of the Article :
INTRODUCTION AND HYPOTHESIS: To determine if abobotulinumtoxin A (AboBTXA) is an effective treatment for interstitial cystitis/bladder pain syndrome (IC/BPS). METHODS: We performed a double-blind study of 54 women with severe, refractory IC from three referral centres whom we randomly allocated to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00192-013-2267-8

データ提供：米国国立医学図書館（NLM）

AboBTXA for Refractory IC/BPS: A Double-Blind Study

This multicenter, double-blind study investigates the efficacy of abobotulinumtoxin A (AboBTXA) in treating refractory interstitial cystitis/bladder pain syndrome (IC/BPS). The researchers evaluated the effects of AboBTXA on patient symptoms and quality of life, exploring its potential as a treatment option for this challenging condition.

AboBTXA: A Promising Treatment for Refractory IC/BPS

While the study did not show a significant overall improvement in symptom scores, the researchers observed a positive response in a subset of patients with refractory IC/BPS. This finding suggests that AboBTXA might be beneficial for a specific group of patients who have not responded to other treatments. The study also highlights the importance of managing urinary tract infections (UTIs) as they can significantly impact the effectiveness of the treatment.

Navigating IC/BPS Treatment: A Complex Journey

This research, like a journey across a vast and complex desert, highlights the challenges associated with managing IC/BPS. It underscores the need for individualized treatment approaches and the importance of addressing potential confounding factors like UTIs. The study's findings suggest that AboBTXA might offer a valuable therapeutic option for a subset of patients, but further research is necessary to fully understand its effectiveness and optimal use.

Dr.Camel's Conclusion

This study, like a camel caravan seeking a hidden oasis in the desert, underscores the ongoing search for effective treatments for IC/BPS. While AboBTXA shows promise for a subset of patients, further research is needed to refine its use and optimize its effectiveness. This research reminds us that finding solutions for challenging conditions like IC/BPS requires a persistent and collaborative effort, much like a camel caravan working together to overcome the obstacles of the desert landscape.

Date :
  1. Date Completed 2014-12-29
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24276074

DOI: Digital Object Identifier

10.1007/s00192-013-2267-8

Related Literature

Article Analysis
・Effective treatment of interstitial cystitis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.